Enabling the development of new therapeutic products, Avectas' vector-free technology demonstrates highly efficient and reproducible intracellular delivery by a finely controlled dispersal of therapeutic agents such as proteins, antibodies, siRNA, mRNA, DNA and editing tools to human primary immune and stem cells ex-vivo.

Among our developing suite of delivery technologies we are also developing cGMP cell encapsulation capability for engineered cells at scale.

Focusing on the areas of gene editing, cell therapy and immune therapy, our core objective is to enable innovative therapies to reach the patient.